'Gene-dose' effect for Alzheon's ALZ-801, a drug targeting Alzheimer's disease

25 October 2016

Closely-held US biotech firm Alzheon has announced the publication of data that shows for the first time a ‘gene-dose’ effect for a drug targeting Alzheimer’s disease to treat a subpopulation of up to 65% of Alzheimer’s patients with a genetic risk factor.

Based on these results, Alzheon is advancing its drug candidate tramiprosate into Phase III clinical studies to seek approval of a new drug for Alzheimer’s disease.

Back in 2007, Canadian drugmaker Neurochem abandoned development of its Alzheimer's disease drug candidate Alzhemed (tramiprosate), on the basis that data from the program was unlikely to be sufficient for regulatory approval. Alzheon was launched in October 2013, when is gained rights to ALZ-801, an oral prodrug of tramiprosate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK